Drug profile · INN
roflumilast
DAXAS
roflumilast (DAXAS) is a phosphodiesterase 4 inhibitor. Associated with Arcutis Biotherapeutics. Route of administration: topical. Current US regulatory status: approved.
Drug details — roflumilast
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- TOPICAL
- Patents
- 20
- Programs
- 21
- Data quality
- 0.89
Quick answer
roflumilast (DAXAS) is a phosphodiesterase 4 inhibitor. Associated with Arcutis Biotherapeutics. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: Phosphodiesterase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12390453
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 12336983
Inhibition of crystal growth of roflumilast
granted -
US 12329751
Topical roflumilast formulation having antifungal properties
granted -
US 12310956
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 12257242
Inhibition of crystal growth of roflumilast
granted -
US 12220409
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12144802
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
granted -
US 12053481
Compositions and methods for deep dermal drug delivery
granted -
US 12042487
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 12042558
Method and formulation for improving roflumilast skin penetration lag time
granted -
US 12016848
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12011437
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12005052
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 12005051
Topical roflumilast formulation having improved delivery and plasma half life
granted -
US 11992480
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 11819496
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 11793796
Inhibition of crystal growth of roflumilast
granted -
US 11707454
Topical roflumilast formulation having antifungal properties
granted -
US 11628177
Compositions and methods for deep dermal drug delivery
granted -
US 11534493
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
granted
Frequently asked questions
What is roflumilast?
roflumilast (DAXAS) is a phosphodiesterase 4 inhibitor. Associated with Arcutis Biotherapeutics. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for roflumilast?
DAXAS is a marketed brand name for roflumilast. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of roflumilast?
roflumilast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.